Author(s):
Shruthi Suvarna H I, Vishakh R, Shailaja S Moodithaya
Email(s):
moodithayashailaja12@gmail.com
DOI:
10.52711/0974-360X.2023.00313 
Address:
Shruthi Suvarna H I1, Vishakh R2, Shailaja S Moodithaya3*
1Department of Physiology, A J Institute of Medical Sciences and Research Centre, Kuntikana, Mangalore - 575004, Karnataka, India.
2Central Research Laboratory, KS Hegde Medical Academy, Nitte (Deemed to be) University, Mangalore - 575018, Karnataka, India.
3Department of Physiology, KS Hegde Medical Academy, Nitte (Deemed to be) University, Mangalore - 575018, Karnataka, India.
*Corresponding Author
Published In:
Volume - 16,
Issue - 4,
Year - 2023
ABSTRACT:
Background: Type 2 Diabetes Mellitus is a metabolic disorder associated with excessive free radical generation and oxidative stress. Pharmacological interventions of T2DM targets on glycemic control and reduce the circulatory levels of oxidative stress and inflammation. Aim: The study compared the levels of oxidative stress, inflammation and the extent of DNA damage in T2DM patients undergoing different treatment modalities. Methods: 150 subjects recruited for this study belonged to the age group of 35-65 years. Participants were grouped as healthy controls (n=50), diabetics treated with oral hypoglycemic agent metformin (n=50) and diabetics undergoing combined therapy of insulin and metformin (n = 50). All the participants underwent the assessment of anthropometric measures, baseline blood pressure and blood samples were analysed for FBS, HbA1c, MDA, TAC, Hs-CRP and DNA damage. Results: Analysis using one-way ANOVA showed that despite the same age and duration of T2DM, patients in insulin therapy group had significantly higher levels of oxidative stress, inflammation and DNA damage when compared to T2DM patients treated with metformin alone. Further, significant correlations were observed for the above parameters with the duration of T2DM.Conclusion: The study concludes that oxidative stress, systemic inflammation and cellular senescence are more prominent in T2DM patients undergoing insulin therapy. Poor glycemic control observed in these patients could be attributed to increased insulin resistance as a consequence of oxidative stress and inflammation.
Cite this article:
Shruthi Suvarna H I, Vishakh R, Shailaja S Moodithaya. Indices of Inflammation, Oxidative Stress and DNA damage in T2DM patients with and without Insulin Therapy. Research Journal of Pharmacy and Technology 2023; 16(4):1907-2. doi: 10.52711/0974-360X.2023.00313
Cite(Electronic):
Shruthi Suvarna H I, Vishakh R, Shailaja S Moodithaya. Indices of Inflammation, Oxidative Stress and DNA damage in T2DM patients with and without Insulin Therapy. Research Journal of Pharmacy and Technology 2023; 16(4):1907-2. doi: 10.52711/0974-360X.2023.00313 Available on: https://rjptonline.org/AbstractView.aspx?PID=2023-16-4-62
REFERENCES:
1. Ahmed N. Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Research and Clinical Practice. 2005; 67:3–21.
2. Dar BA. Hemoglobin A1C and aging, Hemoglobin A1C anti aging tool, HBA1C, HBA1C Biomarker. Indian Journal of Applied Research 2015; 5:19–21.
3. Saha D, Tamrakar A. Xenobiotics, Oxidative Stress, Free Radicals Vs. Antioxidants: Dance Of Death to Heaven’s Life. Asian Journal of Research in Pharmaceutical Sciences. 2011; 1:36–8.
4. Banerjee S, Bhattacharyya S. Oxidative stress parameters and antioxidant status in middle aged amd elderly subjects: an age-related comparative study. Int J Bioassays 2014; 3:3131–6.
5. Bikkad MD, Somwanshi SD, S, Ghuge eep H, Nagane NS. Oxidative Stress in Type II Diabetes Mellitus. Biomedical Research. 2014; 25:84–7.
6. Devaraj S, Singh U, Jialal I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20:182–9.
7. Kg K, Nv S, Dk B, Vr U, Av B. Diabetes Macroangiopathy- A Review. Research Journal of Pharmacology and Pharmacodynamics. 2009; 1:45–9.
8. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018; 17:83.
9. Yamada S. Distribution of Serum C-Reactive Protein and Its Association with Atherosclerotic Risk Factors in a Japanese Population : Jichi Medical School Cohort Study. American Journal of Epidemiology 2001; 153:1183–90. doi/10.1093/aje/153.12.1183
10. Cottone S, Mule G, Nardi E, Vadala A, Guarneri M, Briolotta C, Arsena R, Palermo A, Riccobene R, Cerasola G. Relation of C-Reactive Protein to Oxidative Stress and to Endothelial Activation in Essential Hypertension. American Journal of Hypertension 2006; 19:313–8. doi/10.1016/j.amjhyper.2005.09.005
11. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, Igelmann H, Lu X, Soron G, Cooper B, Brayton C, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature. 2002; 415:45–53. doi/10.1038/415045a
12. Bernadotte A, Mikhelson VM, Spivak IM. Markers of cellular senescence. Telomere shortening as a marker of cellular senescence. Aging. 2016; 8:3–11. doi/10.18632/aging.100871
13. Pradhan AD. C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus. JAMA. 2001; 286:327. doi/10.1001/jama.286.3.327
14. Vadivelan R, Umasankar P, Dipanjan M, Shanish A, Dhanabal S, Elango K. Oxidative Stress Induced Diabetic Nephropathy. Research J Pharmacology and Pharmacodynamics 2010; 2:321–3.
15. Bailey C. The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future. Clin Pharmacol Ther 2015; 98:170–84. doi/10.1002/cpt.144
16. Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and ageing: improving ageing outcomes beyond glycaemic control. Diabetologia. 2017; 60:1630–8. doi/10.1007/s00125-017-4349-5
17. Khan MY, Gupta P, Bihari B, Verma VK. A Review on Diabetes and Its Management. Asian Journal of Pharmaceutical Research. 2013; 3:27–32.
18. Akintola AA, van Heemst D. Insulin, Aging, and the Brain: Mechanisms and Implications. Front Endocrinol. 2015; 6. doi/10.3389/fendo.2015.00013.
19. Reaven GM. Compensatory Hyperinsulinemia and the Development of an Atherogenic Lipoprotein Profile: The Price Paid to Maintain Glucose Homeostasis in Insulin-Resistant Individuals. Endocrinology and Metabolism Clinics of North America. 2005; 34:49–62. doi/ 10.1016/j.ecl.2004.12.001.
20. Bigagli E, Lodovici M. Circulating Oxidative Stress Biomarkers in Clinical Studies on Type 2 Diabetes and Its Complications. Oxidative Medicine and Cellular Longevity. 2019; 2019:1–17. doi/10.1155/2019/5953685.
21. Vadivelan R, Dhanabal Sp, Rajeswari R, Shanish A, Elango K, Suresh B. Oxidative Stress in Diabetes- A Key Therapeutic Agent. Research Journal of Pharmacology and Pharmacodynamics. 2010; 2:221–7.
22. Sutrakar SK, Baghel DS. Biochemical Parameters Variations in Type–II Diabetes Mellitus: Special Reference in Rewa Region. Asian Journal of Research in Chemistry. 2014; 7:877–81.
23. Kim SG, Kim NH, Ku BJ, Shon HS, Kim DM, Park TS, Kim Y-S, Kim IJ, Choi DS. Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea. J Diabetes Investig. 2017; 8:346–53. doi/10.1111/jdi.12581
24. Esmaillzadeh A, Mirmiran P, Azizi F. Waist-to-hip ratio is a better screening measure for cardiovascular risk factors than other anthropometric indicators in Tehranian adult men. Int J Obes. 2004; 28:1325–32. dio/10.1038/sj.ijo.0802757
25. Mohsen H, Shaden H, Faiza AQ, Taghrid H. Correlation of serum leptin levels with insulin resistance in Syrian obese patients with type 2 diabetes mellitus. Research Journal of Pharmacy and Technology.2013; 6:1149–51.
26. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS. Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 2001. JAMA. 2003; 289:76. doi/10.1001/jama.289.1.76.
27. Wang J, Thornton JC, Kolesnik S, Pierson RN. Anthropometry in Body Composition: An Overview. Annals of the New York Academy of Sciences. 2006; 904:317–26. doi/10.1111/j.1749-6632.2000.tb06474.x
28. Amador-Licona N, Guı́zar-Mendoza J-M, Vargas E, Sánchez-Camargo G, Zamora-Mata L. The Short-Term Effect of a Switch from Glybenclamide to Metformin on Blood Pressure and Microalbuminuria in Patients with Type 2 Diabetes Mellitus. Archives of Medical Research 2000; 31:571–5. doi/10.1016/S0188-4409(00)00241-1
29. DeFronzo RA. The effect of insulin on renal sodium metabolism: A review with clinical implications. Diabetologia. 1981; 21. doi/10.1007/BF00252649.
30. Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018; 122:624–38. doi/10.1161/CIRCRESAHA.117.311586
31. Crofts CAP. Hyperinsulinemia: A unifying theory of chronic disease? Diabesity. 2015; 1:34. doi/ 10.15562/diabesity.2015.19
32. Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature. 2006; 440:944–8. doi/10.1038/nature04634
33. Palem SP. A Study on the Level of Oxidative Stress and Inflammatory Markers in Type 2 Diabetes Mellitus Patients with Different Treatment Modalities. JCDR. 2015; 440:944–8. doi/ 10.7860/JCDR/2015/14218.6449
34. Shi L, Tan G-S, Zhang K. Relationship of the Serum CRP Level With the Efficacy of Metformin in the Treatment of Type 2 Diabetes Mellitus: A Meta-Analysis: Serum CRP Levels and Metformin Efficacy in T2DM. J Clin Lab Anal. 2016; 30:13–22. doi/10.1002/jcla.21803
35. Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014; 232:156–64. doi/10.1016/j.atherosclerosis.2013.10.025
36. King DE, Mainous AG, Buchanan TA, Pearson WS. C-Reactive Protein and Glycemic Control in Adults With Diabetes. Diabetes Care. 2003; 26:1535–9. doi/10.2337/diacare.26.5.1535
37. Kushwaha SP, Rawat SK, Kumar P, Abhishek, Tripathi K. Coupling Antioxidant and Antidiabetic assets of 2, 4-Thiazolidinedione Derivatives. Asian Journal of Pharmaceutical Analysis. 2011; 1:71–3.
38. Singh NP, McCoy MT, Tice RR, Schneider EL. A simple technique for quantitation of low levels of DNA damage in individual cells. Experimental Cell Research. 1988; 175:184–91. doi/ 10.1016/0014-4827(88)90265-0
39. Algire C, Moiseeva O, Deschênes-Simard X, Amrein L, Petruccelli L, Birman E, Viollet B, Ferbeyre G, Pollak MN. Metformin Reduces Endogenous Reactive Oxygen Species and Associated DNA Damage. Cancer Prevention Research. 2012; 5:536–43. doi/ 10.1158/1940-6207.CAPR-11-0536
40. Amador RR, Longo JPF, Lacava ZG, Dórea JG, Santos M de FMA. Metformin (dimethyl-biguanide) induced DNA damage in mammalian cells. Genet Mol Biol; 2011; 35:153–8. dio/10.1590/S1415-47572011005000060
41. Nasri H, Rafieian-Kopaei M. Metformin: Current knowledge. J Res Med Sci 2014; 19:658–64.
42. Tornovsky-Babeay S, Dadon D, Ziv O, Tzipilevich E, Kadosh T, Schyr-Ben Haroush R, et al Type 2 Diabetes and Congenital Hyperinsulinism Cause DNA Double-Strand Breaks and p53 Activity in β Cells. Cell Metabolism. 2014; 19:109–21. doi/10.1016/j.cmet.2013.11.007
43. Wilson S, Symphoria S. A Study to assess the effect of awareness Programme on Compliance to Insulin Therapy among Patients with Diabetes Mellitus (DM) in a Selected Community Health Centre, Thrissur District. Asian Journal of Nursing Education and Research. 2016; 6:464–70.
44. Hu Y, Li L, Xu Y, Yu T, Tong G, Huang H, Bi Y, Weng J, Zhu D. Short-Term Intensive Therapy in Newly Diagnosed Type 2 Diabetes Partially Restores Both Insulin Sensitivity and β-Cell Function in Subjects With Long-Term Remission. Diabetes Care. 2011; 34:1848–53. doi/10.2337/dc10-2105
45. Fung J, Berger A. Hyperinsulinemia and Insulin Resistance: Scope of the Problem. J insul resist. 2016; 1:a18. doi/10.4102/jir.v1i1.18